|
1
|
Zambo I and Vesely K: WHO classification
of tumours of soft tissue and bone 2013: The main changes compared
to the 3rd edition. Cesk Patol. 50:64–70. 2014.(In Czech).
PubMed/NCBI
|
|
2
|
Hu K, Wang Z, Lin P, Wen Z, Ren H, Sun L,
Li H, Li B, Wang S, Zhou X, et al: Three hematological indexes that
may serve as prognostic indicators in patients with primary,
high-grade, appendicular osteosarcoma. Oncotarget. 8:43130–43139.
2017.PubMed/NCBI
|
|
3
|
Li GL, Wu YX, Li YM and Li J: High
expression of long non-coding RNA XIST in osteosarcoma is
associated with cell proliferation and poor prognosis. Eur Rev Med
Pharmacol Sci. 21:2829–2834. 2017.PubMed/NCBI
|
|
4
|
Wu Y, Wu J, Dong QR and Guo NZ:
Association between expression of nuclear receptor co-activator 5
protein and prognosis in postoperative patients with osteosarcoma.
Oncol Lett. 15:1888–1892. 2018.PubMed/NCBI
|
|
5
|
Tao Y, Xin M, Cheng H, Huang Z, Hu T,
Zhang T and Wang J: TRIM37 promotes tumor cell proliferation and
drug resistance in pediatric osteosarcoma. Oncol Lett.
14:6365–6372. 2017.PubMed/NCBI
|
|
6
|
Lu J, Song G, Tang Q, Yin J, Zou C, Zhao
Z, Xie X, Xu H, Huang G, Wang J, et al: MiR-26a inhibits stem
cell-like phenotype and tumor growth of osteosarcoma by targeting
Jagged1. Oncogene. 36:231–241. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu X, Zhou X, Xu H, He Z, Shi X and Wu S:
SLC34A2 regulates the proliferation, migration, and invasion of
human osteosarcoma cells through PTEN/PI3K/AKT signaling. DNA Cell
Biol. 36:775–780. 2017.PubMed/NCBI
|
|
8
|
Cao J, Han X, Qi X, Jin X and Li X: TUG1
promotes osteosarcoma tumorigenesis by upregulating EZH2 expression
via miR-144-3p. Int J Oncol. 51:1115–1123. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao YX, Wang YS, Cai QQ, Wang JQ and Yao
WT: Up-regulation of HDAC9 promotes cell proliferation through
suppressing p53 transcription in osteosarcoma. Int J Clin Exp Med.
8:11818–11823. 2015.PubMed/NCBI
|
|
10
|
Kong JS, Kim HJ, Kim MJ, Kim A, Lee D, Han
K, Park S, Koh JS and Myung JK: The significance of TROP2
expression in predicting braf mutations in papillary thyroid
carcinoma. J Pathol Transl Med. 52:14–20. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao W, Zhu H, Zhang S, Yong H, Wang W,
Zhou Y, Wang B, Wen J, Qiu Z, Ding G, et al: Trop2 is overexpressed
in gastric cancer and predicts poor prognosis. Oncotarget.
7:6136–6145. 2016.PubMed/NCBI
|
|
12
|
Shvartsur A and Bonavida B: Trop2 and its
overexpression in cancers: Regulation and clinical/therapeutic
implications. Genes Cancer. 6:84–105. 2015.PubMed/NCBI
|
|
13
|
Lin H, Zhang H, Wang J, Lu M, Zheng F,
Wang C, Tang X, Xu N, Chen R, Zhang D, et al: A novel human Fab
antibody for Trop2 inhibits breast cancer growth in vitro and in
vivo. Int J Cancer. 134:1239–1249. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mao Y, Wang X, Zheng F, Wang C, Tang Q,
Tang X, Xu N, Zhang H, Zhang D, Xiong L, et al: The
tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate
in pancreatic cancer. Oncotarget. 7:24810–24823. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fong D, Moser P, Krammel C, Gostner JM,
Margreiter R, Mitterer M, Gastl G and Spizzo G: High expression of
TROP2 correlates with poor prognosis in pancreatic cancer. Br J
Cancer. 99:1290–1295. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mühlmann G, Spizzo G, Gostner J, Zitt M,
Maier H, Moser P, Gastl G, Zitt M, Müller HM, Margreiter R, et al:
TROP2 expression as prognostic marker for gastric carcinoma. J Clin
Pathol. 62:152–158. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Inamura K, Yokouchi Y, Kobayashi M,
Ninomiya H, Sakakibara R, Subat S, Nagano H, Nomura K, Okumura S,
Shibutani T and Ishikawa Y: Association of tumor TROP2 expression
with prognosis varies among lung cancer subtypes. Oncotarget.
8:28725–28735. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pak MG, Shin DH, Lee CH and Lee MK:
Significance of EpCAM and TROP2 expression in non-small cell lung
cancer. World J Surg Oncol. 10:532012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu B, Yu C, Zhou B, Huang T, Gao L, Liu T
and Yang X: Overexpression of TROP2 promotes proliferation and
invasion of ovarian cancer cells. Exp Ther Med. 14:1947–1952. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ohmachi T, Tanaka F, Mimori K, Inoue H,
Yanaga K and Mori M: Clinical significance of TROP2 expression in
colorectal cancer. Clin Cancer Res. 12:3057–3063. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sukhthankar M, Alberti S and Baek SJ:
(−)-Epigallocatechin-3-gallate (EGCG) post-transcriptionally and
post-translationally suppresses the cell proliferative protein
TROP2 in human colorectal cancer cells. Anticancer Res.
30:2497–2503. 2010.PubMed/NCBI
|
|
22
|
Cubas R, Zhang S, Li M, Chen C and Yao Q:
Trop2 expression contributes to tumor pathogenesis by activating
the ERK MAPK pathway. Mol Cancer. 9:2532010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW,
Yun JP, Zhang MF and Wan DS: Elevated expressions of MMP7, TROP2,
and survivin are associated with survival, disease recurrence, and
liver metastasis of colon cancer. Int J Colorectal Dis. 24:875–884.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guan H, Guo Z, Liang W, Li H, Wei G, Xu L,
Xiao H and Li Y: Trop2 enhances invasion of thyroid cancer by
inducing MMP2 through ERK and JNK pathways. BMC Cancer. 17:4862017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chiang SF, Kan CY, Hsiao YC, Tang R, Hsieh
LL, Chiang JM, Tsai WS, Yeh CY, Hsieh PS, Liang Y, et al: Bone
marrow stromal antigen 2 is a novel plasma biomarker and
prognosticator for colorectal carcinoma: A secretome-based
verification study. Dis Markers. 2015:8740542015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang J, Zhu Z, Wang H, Li F, Du X and Ma
RZ: Trop2 regulates the proliferation and differentiation of murine
compact-bone derived MSCs. Int J Oncol. 43:859–867. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eisenwort G, Jurkin J, Yasmin N, Bauer T,
Gesslbauer B and Strobl H: Identification of TROP2 (TACSTD2), an
EpCAM-like molecule, as a specific marker for TGF-β1-dependent
human epidermal Langerhans cells. J Invest Dermatol. 131:2049–2057.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wen ZQ, Li XG, Zhang YJ, Ling ZH and Lin
XJ: Osteosarcoma cell-intrinsic colony stimulating factor-1
receptor functions to promote tumor cell metastasis through JAG1
signaling. Am J Cancer Res. 7:801–815. 2017.PubMed/NCBI
|
|
29
|
Gong C, Liao H, Wang J, Lin Y, Qi J, Qin
L, Tian LQ and Guo FJ: LY294002 induces G0/G1 cell cycle arrest and
apoptosis of cancer stem-like cells from human osteosarcoma via
down-regulation of PI3K activity. Asian Pac J Cancer Prev.
13:3103–3107. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Han G, Wang Y and Bi W: C-Myc
overexpression promotes osteosarcoma cell invasion via activation
of MEK-ERK pathway. Oncol Res. 20:149–156. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu Y, Cheng Z, Pan F and Yan W:
MicroRNA-373 promotes growth and cellular invasion in osteosarcoma
cells by activation of the PI3K/AKT-Rac1-JNK pathway: The potential
role in spinal osteosarcoma. Oncol Res. 25:989–999. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Son S, Shin S, Rao NV, Um W, Jeon J, Ko H,
Deepagan VG, Kwon S, Lee JY and Park JH: Anti-Trop2
antibody-conjugated bioreducible nanoparticles for targeted triple
negative breast cancer therapy. Int J Biol Macromol. 110:406–415.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen MB, Wu HF, Zhan Y, Fu XL, Wang AK,
Wang LS and Lei HM: Prognostic value of TROP2 expression in
patients with gallbladder cancer. Tumour Biol. 35:11565–11569.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guan GF, Zhang DJ, Wen LJ, Yu DJ, Zhao Y,
Zhu L, Guo YY and Zheng Y: Prognostic value of TROP2 in human
nasopharyngeal carcinoma. Int J Clin Exp Pathol. 8:10995–11004.
2015.PubMed/NCBI
|
|
35
|
Liu X, Li S and Yi F: Trop2 gene: A novel
target for cervical cancer treatment. J Cancer Res Clin Oncol.
140:1331–1341. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ma J, Huang H, Han Z, Zhu C and Yue B:
RLN2 Is a positive regulator of AKT-2-induced gene expression
required for osteosarcoma cells invasion and chemoresistance.
Biomed Res Int. 2015:1474682015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang H, Luo QF, Peng AF, Long XH, Wang TF,
Liu ZL, Zhang GM, Zhou RP, Gao S, Zhou Y and Chen WZ: Positive
feedback regulation between Akt phosphorylation and fatty acid
synthase expression in osteosarcoma. Int J Mol Med. 33:633–639.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Graziano AC, Cardile V, Avola R, Vicario
N, Parenti C, Salvatorelli L, Magro G and Parenti R: Wilms' tumor
gene 1 silencing inhibits proliferation of human osteosarcoma MG-63
cell line by cell cycle arrest and apoptosis activation.
Oncotarget. 8:13917–13931. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Huang S and Jin A: ZIC2 promotes viability
and invasion of human osteosarcoma cells by suppressing SHIP2
expression and activating PI3K/AKT pathways. J Cell Biochem.
119:2248–2257. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li X, Teng S, Zhang Y, Zhang W, Zhang X,
Xu K, Yao H, Yao J, Wang H, Liang X and Hu Z: TROP2 promotes
proliferation, migration and metastasis of gallbladder cancer cells
by regulating PI3K/AKT pathway and inducing EMT. Oncotarget.
8:47052–47063. 2017.PubMed/NCBI
|
|
41
|
Lin JC, Wu YY, Wu JY, Lin TC, Wu CT, Chang
YL, Jou YS, Hong TM and Yang PC: TROP2 is epigenetically
inactivated and modulates IGF-1R signalling in lung adenocarcinoma.
EMBO Mol Med. 4:472–485. 2012. View Article : Google Scholar : PubMed/NCBI
|
